PT-141 (Bremelanotide)

Mechanism

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide analog of α-MSH, structurally related to Melanotan-II but specifically engineered to lose the MC1R agonism (which produces tanning) while retaining MC3R and MC4R activity (which mediate central nervous system effects on sexual function and appetite).

The mechanism for sexual function is centrally mediated — MC4R activation in hypothalamic nuclei modulates downstream neural pathways involving dopamine and nitric oxide that contribute to sexual arousal. Unlike PDE-5 inhibitors (sildenafil, tadalafil) that act on peripheral vasculature, bremelanotide acts in the brain.

This mechanistic distinction is significant clinically: bremelanotide produces sexual-desire effects (in women) and erectile effects (in men, off-label) without the cardiovascular interactions of PDE-5 inhibitors with nitrates. It also has an entirely different adverse-event profile, dominated by nausea and transient blood pressure elevation rather than the headache/flushing/dyspepsia of PDE-5 inhibitors.

Half-life is approximately 2.7 hours; it is administered as a single subcutaneous injection 45 minutes before anticipated sexual activity.

What the evidence shows

Phase 3 RECONNECT trials (Kingsberg SA et al, Obstet Gynecol 2019):

Two identical 24-week double-blind RCTs in premenopausal women with acquired HSDD, total ~1,200 patients. Primary endpoints were change in sexual desire (FSFI desire domain) and change in distress related to low desire (FSDS-DAO).

Both endpoints reached statistical significance, with effect sizes that were modest but clinically meaningful. Notable: the placebo response was substantial (consistent with sexual function trials generally), and the absolute difference between bremelanotide and placebo was smaller than the absolute placebo response. This is a real-world tension in this drug class — the response is real, but the placebo response is real too.

For off-label use in men (erectile dysfunction):

Older Phase 2 work (Wessells et al, late 1990s / early 2000s) showed bremelanotide produced erections in men with psychogenic erectile dysfunction. Effect sizes were modest, and a Phase 3 program in men with ED was discontinued — primarily because of blood pressure elevation concerns at doses needed for consistent effect.

The body of evidence for women’s HSDD is substantially stronger than for men’s ED.

Dosing literature

Approved dosing (subcutaneous, on-demand):

• Vyleesi (premenopausal women, HSDD): 1.75 mg subcutaneous, autoinjector, taken at least 45 minutes before anticipated sexual activity. No more than one dose per 24 hours; no more than 8 doses per month.

Off-label male use protocols are typically lower (0.5–1 mg) to minimize blood pressure and nausea effects, taken on a similar pre-activity timing.

Risks and adverse events

Common (Vyleesi label):

• Nausea (~40% — the most common reason for discontinuation)
• Flushing
• Injection-site reactions
• Headache
• Vomiting
• Cough
• Fatigue
• Transient hyperpigmentation (focal, ~1% — particularly on face, gums, breasts)

Less common but clinically significant:

• Transient blood pressure elevation — average ~6/3 mmHg increase, peaks around hour 4 post-dose, returns to baseline by 12 hours. Contraindicated in patients with uncontrolled hypertension or cardiovascular disease.
• Heart rate increase — modest, dose-dependent
• Focal hyperpigmentation — generally on face, gums, areolae; usually resolves on discontinuation but may persist

Distinguishing from Melanotan-II:

Both are melanocortin agonists; both can cause some hyperpigmentation. The PT-141 hyperpigmentation is typically focal and limited because the engineering specifically reduces MC1R activity. It is not a tanning drug. Patients seeking tanning effects from PT-141 are unlikely to get them and likely to experience the adverse-event profile without the desired outcome.

Regulatory status

The narrower-than-US approval landscape reflects regulatory disagreement about whether the modest effect sizes justify approval given the adverse event profile.

Where to get it

For the approved indication: through a clinician (gynecology or sexual medicine) with prescription. Vyleesi is available through specialty distribution.

For off-label use, the legitimate path is a clinician relationship and prescribed therapy with cardiovascular screening and monitoring (the BP elevation matters in patients with underlying cardiovascular risk, and most users don’t get baseline assessment).

The gray-market “PT-141” sold by research-peptide vendors carries the typical quality concerns. Mass-spec testing has found incorrect sequences, wrong concentrations, and contamination at rates consistent with the broader gray-market peptide channel.

We have no fulfillment partner for PT-141 at this time. (See How we make money.)

References (selected)

1. Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019. PubMed
2. Clayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health 2016.
3. Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006.
4. Wessells H et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998.
5. FDA prescribing information, Vyleesi — current revision.